Hemab Therapeutics Holdings, Inc.: insider trades · United States · SEC (Form 4)

About Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company listed in the United States on the NASDAQ market (United States), focused on developing novel therapies for blood coagulation disorders. For French, Belgian, and Swiss investors, Hemab should be viewed as a high-R&D, specialized biotech platform addressing rare and underserved bleeding and thrombotic diseases. The company says it is based in Cambridge, Massachusetts, while also maintaining an operating presence in Copenhagen, Denmark, which reflects both its Nordic origins and its now more global corporate footprint. ([ir.hemab.com](https://ir.hemab.com/)) Hemab’s corporate history, in its current public-company form, is very recent. The SEC prospectus states that Hemab Therapeutics Holdings, Inc. was incorporated in Delaware on February 12, 2026, and that in March 2026 the company completed a reorganization in which the Danish parent, Hemab ApS, became a wholly owned subsidiary. Prior to that transaction, the business operated as Hemab ApS, a private limited company organized under the laws of the Kingdom of Denmark. This matters from an equity-analysis perspective because the listed entity is still in an early public-market phase, with the operating history largely tied to its private-company predecessor. ([sec.gov](https://www.sec.gov/Archives/edgar/data/2114044/000119312526201458/d50309d424b4.htm)) From a business-model standpoint, Hemab is building prophylactic therapies designed to reimagine treatment in coagulation disorders. Its lead candidate, sutacimig, previously known as HMB-001, is a bispecific antibody being developed for prophylactic use in Glanzmann thrombasthenia. The company is also advancing HMB-002, a monovalent antibody program aimed at von Willebrand disease, while continuing to expand a broader pipeline in factor VII deficiency, Bernard-Soulier syndrome, hereditary hemorrhagic telangiectasia, congenital antithrombin III deficiency, and other serious hematology indications. Hemab’s platform relies on monoclonal and bispecific antibody-based approaches, positioning it in a differentiated segment of rare-disease biotech. ([hemab.com](https://www.hemab.com/news-items/hemab-therapeutics-receives-fda-breakthrough-therapy-designation-for-sutacimig-in-glanzmann-thrombasthenia?utm_source=openai)) Competitive positioning is centered on unmet need. Hemab is targeting diseases where existing prophylactic options are limited or absent, which gives its programs the potential to establish meaningful clinical and commercial differentiation if efficacy and safety continue to translate. In March 2026, the FDA granted Breakthrough Therapy Designation to sutacimig for preventing bleeding episodes in Glanzmann thrombasthenia, following earlier regulatory recognitions. The company also disclosed positive clinical and preclinical data in 2025, including presentations at ISTH 2025, supporting the internal thesis that its platform may extend beyond a single rare indication. ([hemab.com](https://www.hemab.com/news-items/hemab-therapeutics-receives-fda-breakthrough-therapy-designation-for-sutacimig-in-glanzmann-thrombasthenia?utm_source=openai)) Recent corporate and market events are also notable. Hemab announced an upsized financing round in its private-company phase and later moved toward the public markets, with its SEC registration statement indicating an intended listing on the NASDAQ Global Select Market under the ticker COAG. For investors, that combination of regulatory momentum, broadening pipeline data, and a newly public capital structure makes Hemab an early-stage but potentially important name in rare bleeding-disorder innovation. The key watch items remain clinical readouts, regulatory progress, and capital needs typical of development-stage biotech companies. ([hemab.com](https://www.hemab.com/news-items/hemab-therapeutics-announces-135m-series-b-financing-to-advance-first-prophylactic-treatments-for-underserved-bleeding-and-thrombotic-disorders))